Hakami was president & CEO of GE Healthcare’s $2 billion detection & guidance systems business and led its interventional systems business from 2009 to 2012, according to a press release. Medtronic’s diabetes business put up $1.53 billion in revenues during its last fiscal year ending April 26, 2013.
"I am extremely pleased that Hooman is joining Medtronic and assuming leadership of our diabetes group," president & CEO Omar Ishrak said in prepared remarks. "Our diabetes franchise has a tremendous opportunity to advance its technology leadership toward the artificial pancreas; expand global access of these therapies to new parts of the world; and develop new and impactful partnerships and business models to address the needs of people with diabetes. I have known and worked with Hooman over many years, and know he will bring outstanding leadership to our team."
"It is a pleasure to join and lead the world-class team of professionals within Medtronic’s global diabetes group," Hakami added. "I am truly excited to work with our team, the diabetes community, and our customers in advancing our technology and service solutions to meet the needs of people with diabetes around the world. Medtronic is moving well along the path to an artificial pancreas, and I look forward to accelerating our work both inside and outside the company to make this a reality."